1. Home
  2. AVBH vs OMER Comparison

AVBH vs OMER Comparison

Compare AVBH & OMER Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AVBH
  • OMER
  • Stock Information
  • Founded
  • AVBH 2003
  • OMER 1994
  • Country
  • AVBH United States
  • OMER United States
  • Employees
  • AVBH N/A
  • OMER N/A
  • Industry
  • AVBH
  • OMER Biotechnology: Pharmaceutical Preparations
  • Sector
  • AVBH
  • OMER Health Care
  • Exchange
  • AVBH Nasdaq
  • OMER Nasdaq
  • Market Cap
  • AVBH 273.7M
  • OMER 304.9M
  • IPO Year
  • AVBH N/A
  • OMER 2009
  • Fundamental
  • Price
  • AVBH $25.05
  • OMER $4.17
  • Analyst Decision
  • AVBH Strong Buy
  • OMER Strong Buy
  • Analyst Count
  • AVBH 4
  • OMER 5
  • Target Price
  • AVBH $28.38
  • OMER $18.00
  • AVG Volume (30 Days)
  • AVBH 67.4K
  • OMER 996.0K
  • Earning Date
  • AVBH 08-25-2025
  • OMER 08-14-2025
  • Dividend Yield
  • AVBH N/A
  • OMER N/A
  • EPS Growth
  • AVBH 61.05
  • OMER N/A
  • EPS
  • AVBH 3.07
  • OMER N/A
  • Revenue
  • AVBH $82,088,000.00
  • OMER N/A
  • Revenue This Year
  • AVBH $15.40
  • OMER N/A
  • Revenue Next Year
  • AVBH $16.94
  • OMER $9,040.39
  • P/E Ratio
  • AVBH $8.17
  • OMER N/A
  • Revenue Growth
  • AVBH 21.72
  • OMER N/A
  • 52 Week Low
  • AVBH $19.32
  • OMER $2.95
  • 52 Week High
  • AVBH $26.59
  • OMER $13.60
  • Technical
  • Relative Strength Index (RSI)
  • AVBH N/A
  • OMER 51.46
  • Support Level
  • AVBH N/A
  • OMER $4.07
  • Resistance Level
  • AVBH N/A
  • OMER $4.43
  • Average True Range (ATR)
  • AVBH 0.00
  • OMER 0.25
  • MACD
  • AVBH 0.00
  • OMER -0.04
  • Stochastic Oscillator
  • AVBH 0.00
  • OMER 24.07

About AVBH Avidbank Holdings Inc. Common stock

Avidbank Holdings Inc is a full-service commercial bank. It offers various services such as commercial and industrial lending, venture lending, structured finance, asset-based lending, sponsor finance, real estate construction, and commercial real estate lending.

About OMER Omeros Corporation

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Share on Social Networks: